Close

Patients

Should We Prescribe Nirmatrelvir/r (Paxlovid) to Low-Risk COVID-19 Patients?

The top recommended treatment for high-risk outpatients with COVID-19 in the NIH Guidelines is nirmatrelvir/r (Paxlovid). It’s quite clear why. In the EPIC-HR study, unvaccinated people at high risk for severe outcomes had an 89% reduction in the risk for hospitalization or death compared to placebo. If we just look at mortality — another important endpoint, […]

Read More

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19

Question  Does antiplatelet therapy administered to critically ill patients with COVID-19 improve organ support–free days (a composite end point of in-hospital mortality and duration of intensive care unit–based respiratory or cardiovascular support) up to day 21? Findings  In this bayesian randomized clinical trial that included 1557 patients, antiplatelet therapy with either aspirin […]

Read More

Thousands more patients to access second ground-breaking antiviral

Thousands more vulnerable people are eligible to receive the UK’s second antiviral Paxlovid, which has been added to the PANORAMIC national study. Paxlovid reduced the risk of hospitalisation or death by 88% in clinical trials and is already available directly through the NHS to highest-risk patients The UK has procured […]

Read More

Long‑term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID‑19 and severe hypoxaemia

Purpose:We assessed long‑term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID‑19) and severe hypoxaemia.Methods:We assessed 180‑day mortality and health‑related quality of life (HRQoL) using EuroQoL (EQ)‑5D‑5L index values and EQ visual analogue scale (VAS) in the […]

Read More

Effect of Early Treatment with Ivermectin among Patients with Covid-19

The efficacy of ivermectin in preventing hospitalization or extended observation in an emergency setting among outpatients with acutely symptomatic coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is unclear. METHODS We conducted a double-blind, randomized, placebo-controlled, adaptive platform trial involving symptomatic SARS-CoV-2–positive adults […]

Read More

Timing of COVID-19 Vaccination Crucial for Blood Cancer Patients

The timing of treatment in relation to vaccination is the strongest predictor of COVID-19 vaccine antibody response say the researchers of a new study. For their study, published in Nature Cancer, researchers from the University of Southampton led a UK multicentre prospective observational study (PROSECO) evaluating COVID-19 vaccine responses in individuals with […]

Read More

The COVID Heart—One Year After SARS-CoV-2 Infection, Patients Have an Array of Increased Cardiovascular Risks

An analysis of data from nearly 154 000 US veterans with SARS-CoV-2 infection provides a grim preliminary answer to the question: What are COVID-19’s long-term cardiovascular outcomes? The study, published in Nature Medicine by researchers at the Veterans Affairs (VA) St Louis Health Care System, found that in the year after recovering from the illness’s […]

Read More

‘Vast Majority’ of COVID Patients Wake Up After Mechanical Ventilation

COVID-19 patients who are successfully weaned off a ventilator may take days, or even weeks, to regain consciousness, especially those who experienced episodes of hypoxemia while intubated, a new study shows. “As we started to see the first patients waking up after successful COVID-19 ICU treatments, we also encountered many […]

Read More

Air Trapping: Common in Patients With Long COVID

Small airway disease with air trapping appears to be a long-lasting sequela of SARS-CoV-2 infection, according to a prospective study that compared 100 COVID-19 survivors who had persistent symptoms and 106 healthy control persons. “Something is going on in the distal airways related to either inflammation or fibrosis that is […]

Read More

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19

Question  Among patients at risk of disease progression, does early treatment of mild to moderate COVID-19 with the neutralizing antibody sotrovimab prevent progression to severe disease? Findings  In this randomized clinical trial of 1057 participants, treatment with a single intravenous dose of sotrovimab, compared with placebo, resulted in a statistically significant reduction […]

Read More
Translate »